Analyst Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Corcept Therapeutics and keeping the price target at $145.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Swayampakula Ramakanth has given his Buy rating due to a combination of factors that highlight Corcept Therapeutics’ promising future prospects. The company is poised for significant growth with the anticipated launch of relacorilant for Cushing’s syndrome and ovarian cancer in 2026. Despite recent challenges with Korlym, Corcept’s sales are expected to grow substantially, indicating strong market demand and effective management strategies.
Moreover, relacorilant’s potential is underscored by its successful Phase 3 trials, which demonstrated superior efficacy and safety compared to Korlym. The drug’s multiple patents and orphan drug designation provide it with market exclusivity, enhancing its competitive edge. Additionally, the management’s proven track record in commercializing therapies and expanding their salesforce positions Corcept well for capitalizing on the expanding market opportunities, including the underappreciated ovarian cancer indication.
According to TipRanks, Ramakanth is a 5-star analyst with an average return of 16.8% and a 41.40% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics, Evaxion Biotech, and Personalis.
In another report released on November 17, Piper Sandler also reiterated a Buy rating on the stock with a $121.00 price target.